Medpace Holdings, Inc. $MEDP Shares Sold by Jackson Square Partners LLC

Jackson Square Partners LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 86.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,326 shares of the company’s stock after selling 57,233 shares during the quarter. Jackson Square Partners LLC’s holdings in Medpace were worth $2,927,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Brooklyn Investment Group grew its position in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. increased its stake in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after purchasing an additional 35 shares during the period. IFP Advisors Inc increased its stake in Medpace by 223.3% in the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Medpace in the first quarter valued at about $60,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on MEDP shares. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Jefferies Financial Group increased their price objective on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Finally, Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and increased their price target for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $475.90.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 36,196 shares of the firm’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the transaction, the chief executive officer owned 925,799 shares of the company’s stock, valued at approximately $440,587,744.10. This trade represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 2,000 shares of the business’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $605.01, for a total value of $1,210,020.00. Following the completion of the transaction, the vice president directly owned 65,500 shares of the company’s stock, valued at approximately $39,628,155. This trade represents a 2.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 116,211 shares of company stock valued at $63,569,958. Corporate insiders own 20.30% of the company’s stock.

Medpace Stock Down 0.5%

Shares of MEDP stock opened at $589.15 on Friday. The stock has a market cap of $16.60 billion, a P/E ratio of 41.20, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The business has a fifty day simple moving average of $527.73 and a 200-day simple moving average of $412.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the company earned $3.01 EPS. The firm’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.